Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma

Diseases of the Esophagus

Volumn 20, Issue 2, 2007, Pages 117-122

  Takahashi, Ken ^a   Miyashita, M ^a   Nomura, T ^a   Makino, H ^a   Futami, R ^a   Kashiwabara, M ^a   Katsuta, M ^a   Tajiri, T ^a  

^a NIPPON MEDICAL SCHOOL GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CEA; ELISA; Esophageal carcinoma; SCC Ag; Serump53 antibody

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; PROTEIN ANTIBODY; PROTEIN P53 ANTIBODY; SQUAMOUS CELL CARCINOMA ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNORADIOMETRIC ASSAY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34147129633     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00656.x     Document Type: Article

References (39)

1. Parkin D M, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (Suppl 8): S4-66.
2. Pisani P, Parkin DM, Bray FI, Ferlay J. Estimate of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29.
3. Yamamoto K, Oka M, Hayashi H et al. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 1997; 79: 1647-55.
4. Nakamura T, Ide H, Eguchi R et al. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus 1998; 11: 35-9.
5. Tsuchiya Y, Onda M, Miyashita M, Sasajima K. Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus. Med Oncol 1999; 16: 31-7.
6. Gao H, Wang LD, Zhou Q et al. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Cancer Res 1994; 54: 4342-6.
7. Parenti AR, Rugge M, Frizzera E et al. p53 overexpression in the multistep process of esophageal carcinogenesis. Am J Surg Pathol 1995; 19: 1418-22.
8. Shimada H, Nabeya Y, Okazumi S et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 2002; 132: 41-7.
9. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992; 89: 3439-42.
10. Winter SF, Minna JD, Johnson BE et al. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52: 4168-74.
11. Hagiwara N, Onda M, Miyashita M, Sasajima K. Detection of circulating anti-p53 antibodies in esophageal cancer patients. J Nippon Med Sch 2000; 67: 110-17.
12. Yoshida A, Kawahara S, Nakamura Y et al. p53 protein overexpression and early recurrence of breast cancer. Jpn J Cancer Clin 1995; 41: 966-70.
13. Nagao M, Kanehiro H, Hisanaga M et al. Prognostic significance of p21 and p53 expression in hepatocellular carcinoma. J Nara Med Assoc 2001; 52: 61-9.
14. Shimada H, Kitabayashi H, Nabeya Y et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 2003; 133: 24-31.
15. Japanese Society for Esophageal D. Guide Lines for the Clinical and Pathologic Studies of the Esophagus, 9th edn. Tokyo, Japan: Kanehara and Co., Ltd., 1999; 23.
16. Galizia G, Ferraraccio F, Lieto E et al. Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery. Dis Colon Rectum 2004; 47: 1904-14.
17. Mineo TC, Ambrogi V, Mineo D, Baldi A. Long-term disease-free survival of patients with radically resected thymomas: Relevance of cell-cycle protein expression. Cancer 2005; 104: 2063-71.
18. Mack U, Ukena D, Montenarh M, Sybrecht GW. Serum anti-p53 antibodies in patients with lung cancer. Oncol Rep 2000; 7: 669-74.
19. Saffroy R, Lelong JC, Azoulay D et al. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 1999; 79: 604-10.
20. Shiota G, Ishida M, Noguchi N et al. Circulating p53 antibody in patients with colorectal cancer: Relation to clinicopathologic features and survival. Dig Dis Sci 2000; 45: 122-8.
21. Sanchez-Carbayo M, Chulia MT, Niveiro M et al. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder. Anticancer Res 1999; 19: 3531-7.
22. Gumus E, Erdamar S, Demirel G et al. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 2004; 11: 1070-7.
23. Holm R, Skomedal H, Helland A et al. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol 1993; 169: 21-6.
24. Nuorva K, Soini Y, Kamel D et al. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am J Pathol 1993; 142: 725-32.
25. Hamelin R, Flejou JF, Muzeau F et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994; 107: 1012-18.
26. Symmans PJ, Linehan JM, Brito MJ, Filipe MI. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol 1994; 173: 221-6.
27. Bennett WP, Hollstein MC, Metcalf RA et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992; 52: 6092-7.
28. Ziegler A, Jonason AS, Leffell DJ et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-6.
29. Bosari S, Roncalli M, Viale G et al. p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix. J Pathol 1993; 169: 425-30.
30. Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors: A multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 2003; 97: 682-9.
31. Xu ML, Wu BQ, Zhong HH et al. [Diagnosis of lymph node micrometastases in human lung carcinoma: Determination of p53 gene mutations by polymerase chain reaction-temperature gradient gel electrophoresis (PCR-TGGE)]. Ai Zheng 2004; 23: 794-8.
32. Munck-Wikland E, Kuylenstierna R, Lindholm J, Wahren B. Carcinoembryonic antigen, CA 19-9 and CA 50 in monitoring human squamous cell carcinoma of the esophagus. Anticancer Res 1990; 10: 703-8.
33. McKnight A, Mannell A, Shperling I. The role of carbohydrate antigen 19-9 as a tumour marker of oesophageal cancer. Br J Cancer 1989; 60: 249-51.
34. Kosugi S, Nishimaki T, Kanda T et al. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg 2004; 28: 680-5.
35. Shimada Y, Watanabe G, Kawamura J et al. Clinical Significance of Osteopontin in Esophageal Squamous Cell Carcinoma: Comparison with Common Tumor Markers. Oncology 2005; 68: 285-92.
36. Stockley RA, Shaw J, Whitfield AG et al. Effect of cigarette smoking, pulmonary inflammation, and lung disease on concentrations of carcinoembryonic antigen in serum and secretions. Thorax 1986; 41: 17-24.
37. Ohwada A, Takahashi H, Nagaoka I et al. Effect of cigarette smoke on the mRNA and protein expression of carcinoembryonic antigen (CEA), a possible chemoattractant for neutrophils in human bronchioloalveolar tissues. Thorax 1995; 50: 651-7.
38. Kashiwabara K, Nakamura H, Yokoi T. Chronological change of serum carcinoembryonic antigen (CEA) concentrations and pulmonary function data after cessation of smoking in subjects with smoking-associated CEA abnormality. Clin Chim Acta 2001; 303: 25-32.
39. Shimada H, Nabeya Y, Okazumi S et al. Prediction of survival with squamous cell carcinoma antigen in patients with respectable esophageal squamous cell carcinoma. Surgery 2003; 133: 486-94.